We previously reported a GRN null mutation, originating from a common founder, in multiple Belgian families with frontotemporal dementia (FTD). Here, we used data of a 10-year follow-up study to describe in detail the clinical heterogeneity observed in this extended founder pedigree. We identified 85 patients and 40 unaffected mutation carriers, belonging to 29 branches of the founder pedigree. Most patients (74.4%) were diagnosed with FTD, while others had a clinical diagnosis of unspecified dementia, Alzheimer's dementia or Parkinson's disease. The observed clinical heterogeneity can guide clinical diagnosis, genetic testing and counseling of mutation carriers. Onset of initial symptomatology is highly variable, ranging from age 45 to 80 years. Analysis of known modifiers, suggested effects of GRN rs5848, MAPT H1/H2 and C9orf72 G 4 C 2 repeat length on onset age but explained only a minor fraction of the variability. Contrary, the extended GRN founder family is a valuable source for identifying other onset age modifiers based on exome or genome sequences.
INTRODUCTION
Frontotemporal lobar degeneration (FTLD) is a heterogeneous group of neurodegenerative disorders. Three clinical subtypes have been defined: the behavioral variant of frontotemporal dementia (bvFTD) and the non-fluent and semantic variant of primary progressive aphasia (PPA) (Gorno-Tempini et al., 2011; Rascovsky et al., 2011) . The pathological hallmark of FTLD is neuronal loss in the frontal and temporal lobes of the brain (Neary et al., 2005) . FTLD is a proteinopathy and, based on the nature of the inclusion proteins, five pathological subtypes are recognized. FTLD-tau, with inclusions of microtubule-associated protein tau, and FTLD-TAR DNA binding protein 43 (FTLD-TDP) are the most frequent pathological diagnoses (Mackenzie and Neumann, 2016) . Causal mutations have been identified in six genes, namely granulin (GRN), chromosome 9 open reading M A N U S C R I P T
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4 frame 72 (C9orf72), microtubule-associated protein tau (MAPT), TANK-binding kinase 1 (TBK1), valosin containing protein (VCP) and charged multivesicular body protein 2B (CHMP2B) (Baker et al., 2006; Cruts et al., 2006; Dejesus-Hernandez et al., 2011; Freischmidt et al., 2015; Gijselinck et al., 2012; Gijselinck et al., 2015; Hutton et al., 1998; Poorkaj et al., 1998; Pottier et al., 2015; Renton et al., 2011; Skibinski et al., 2005; Spillantini et al., 1998; Watts et al., 2004) . Variations in these genes have been suggested to modify disease risk, such as the common variation rs5848 in GRN, the H1/H2 haplotype of MAPT and intermediate alleles of 7 to 24 repeat units of the C9orf72 G 4 C 2 repeat (e.g. (Benussi et al., 2014; Borroni et al., 2005; Gijselinck et al., 2012; Rademakers et al., 2008; Verpillat et al., 2002) ). Additionally, a genome-wide association study identified variations in TMEM106B as risk factors for FTLD-TDP (Van Deerlin et al., 2010) .
GRN mutations explain 10 to 25% of all and 3 to 26% of familial FTD patients (http://www.molgen.vib-ua.be/FTDMutations; Cruts et al., 2012; Sieben et al., 2012) . The majority are heterozygous loss-of-function (LOF) mutations that lead to premature stop codons triggering degradation of the mutant transcript. Consequently, reduced GRN levels are measured in blood and cerebrospinal fluid (Finch et al., 2009; Ghidoni et al., 2008; Sleegers et al., 2009) . In brain, FTLD-TDP pathology type A is typically present (Mackenzie and Neumann, 2016) . Clinical phenotypes are diverse, even between patients carrying the same mutation, and include FTD, Alzheimer's dementia (AD), Parkinson's disease (PD) and corticobasal syndrome (e.g. (Brouwers et al., 2007; Kelley et al., 2009) ). Mutation carriers show a high inter-and intrafamilial variability in onset age ranging from 35 to 89 years Cruts and Van Broeckhoven, 2008; Van Swieten and Heutink, 2008) .
This suggests that modifiers influence the disease onset and clinical appearance. Variations near sortilin (SORT1), a receptor of GRN, and prosaposin (PSAP) regulate GRN levels, but their effect on clinical heterogeneity remains unclear (Carrasquillo et al., 2010; Nicholson et al., 2016) .
We identified in an extended Belgian FTD family a GRN founder mutation in the splice donor site of intron 1 (mutation alias IVS1+5 G>C, protein p.0). The mutation prevents splicing of intron 1, leading to nuclear retention and degradation of the mutant transcript, which results in haploinsufficiency M A N U S C R I P T
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Wauters, Van Mossevelde et al. Manuscript 5 (Cruts et al., 2006) . Since its identification, the pedigree has been extended and additional genealogical and clinical data have been gathered. The Belgian GRN founder mutation is one of the most common GRN mutations worldwide, in addition to the p.Arg493X mutation (Rademakers et al., 2007) and the p.Thr272SerfsX10 mutation, which is the most frequent GRN mutation in Italy (Benussi et al., 2009; Benussi et al., 2010; Borroni,B. et al., 2011b) . For all three mutations founder effects have been described (Benussi et al., 2013; Borroni,B. et al., 2011a; Cruts et al., 2006; Rademakers et al., 2007; van der Zee et al., 2006) . The 10-year follow-up study of the Belgian GRN founder pedigree allowed us to describe in detail the clinical heterogeneity of the GRN patient carriers. The observed heterogeneity in onset age and the size of the extended pedigree provided an opportunity to investigate the potential onset age-modifying effects of known genetic modifiers of FTD risk or disease presentation.
MATERIALS AND METHODS
Study population
Index patients were ascertained in Belgium through an ongoing multicenter collaboration of neurology departments and memory clinics partnering in the Belgian Neurology (BELNEU) consortium. Additional patients, referred to the Diagnostic Service Facility for genetic testing, were included. Information on family history of neurodegenerative diseases was gathered for the index patients and relatives were asked to participate in genetic studies. Written informed consent for participation in clinical and genetic studies, and for brain autopsy when appropriate, was obtained from participants and/or their legal guardians. The clinical study protocol and the informed consent forms for patient ascertainment were approved by the local ethics committees of each of the collaborating neurological centers. The genetic and pathological study protocols and informed consent forms were approved by the Ethics Committee of the University Hospital of Antwerp and the University of Antwerp, Belgium.
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FTD, AD or PD diagnoses were made in accordance with the international consensus criteria (Gelb et al., 1999; Gorno-Tempini et al., 2011; McKhann et al., 1984; McKhann et al., 2011; Postuma et al., 2015; Rascovsky et al., 2011) . Patients with a combination of behavioral and language features of FTD at presentation, without clear predominance, were denoted mixed FTD. In addition to index patients, symptomatic relatives with a clinical diagnosis carrying the founder mutation were included in the clinical study. All available clinical records were reviewed by a medical doctor of the research team (S.V.M). A positive familial history was defined as the presence of at least one first degree or two second degree relatives with neurodegenerative disease. The onset age was defined as the age at which first symptoms were noticed by the patient or his partner/relatives. Fig. S1 summarizes the available biomaterials and clinical information.
Genetic screening
Targeted resequencing of genes involved in neurodegeneration
GRN founder mutation carriers and their family members were screened for mutations using parallel screening of a multi-gene panel of neurodegenerative brain disease-related genes (Agilent, https://www.agilent.com). Multiplex PCRs were performed for target enrichment of the coding regions of 17 causal genes and APOE. This was followed by equimolar pooling of the amplicon libraries and purification using Agencourt AMPureXP beads (Beckman Coulter). A universal PCR was performed to incorporate patient-specific barcodes. Samples were pooled and massive parallel sequencing was performed in-house on an Illumina MiSeq platform. Paired-end reads were generated and adapters were trimmed using Fastq-mcf. Reads were aligned to the reference genome hg19 with the Burrows-Wheeler Aligner MEMv0.7.5a (Li and Durbin, 2009) . Variant calling and annotation was performed using GATKv2.4 UnifiedGenotyper and the GenomeComb package (McKenna et al., 2010; Reumers et al., 2012) . We focused on known pathogenic mutations present within the genes APP, PSEN1, PSEN2, GRN, MAPT, TBK1, CHMP2B, VCP, SOD1, TARDBP, FUS, PRNP, SNCA, LRRK2, PARK2, PARK7 Fig. S2 ). Individual III.3 carried both mutations and was unaffected at 65 years. Sibling III.5 carried only the TARDBP mutation and was unaffected at 57 years. According to relatives, the parent II.3 showed a reduction in speech at 80, mutism at age 84 and loss of interest in the surroundings at 85 years. The spouse of II.3 died unaffected at 80 years. The p.G287S mutation has been identified in patients suffering from amyotrophic lateral sclerosis (Corrado et al., 2009; Kabashi et al., 2008; Kenna et al., 2013; Kirby et al., 2010) .
Screening of candidate onset age modifier variations
The gene panel of neurodegenerative brain disease-related genes also targets regions encompassing candidate modifier variations i.e. rs429358 and rs7412 for APOE genotyping, the GRN 3'-untranslated region (UTR) variant rs5848 and MAPT rs1052553 to determine the H1/H2 haplotype, with the A-allele tagging H1 and the G-allele tagging H2 (Baker et al., 1999; Cruts et al., 2005; Rademakers et al., 2005) . We have also genotyped variant rs1800547, with the A-allele tagging H1 and the G-allele tagging H2 (Baker et al. 1999) . With both MAPT variants we obtained the same results, as expected since they are in linkage disequilibrium (R 2 =1 and D'=1, HapMap 22). Other candidate modifier variations in TMEM106B, PSAP, SORT1 and C9orf72 were genotyped using Sanger sequencing on 3730 DNA Analyzers (Applied Biosystems) followed by sequence analysis using SeqMan software (DNASTAR). PCR amplification followed by size separation of amplicons on the 3730 DNA Analyzer was used to determine the size of the (G 4 C 2 ) n repeat in C9orf72. Genotypes were assigned using the in-house developed TracI genotyping software. Individuals who appeared homozygous for the short (≤ 6 units) or intermediate (7-24 units) G 4 C 2 repeat allele were screened with a reverse repeat-primed PCR to detect a possible repeat expansion (Gijselinck et al., 2012) .
Estimation of the effect of risk variations on onset age
Effects of candidate modifier variations on onset age were estimated using a reversible jump Markov chain Monte Carlo algorithm for censored quantitative traits in Loki (Heath, 1997) . In addition to gender, genotypes or haplotypes of candidate modifier variations were entered in the trait model as a fixed major gene covariate to estimate whether a variation can explain the variance in onset age M A N U S C R I P T
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Wauters, Van Mossevelde et al. Manuscript 8 (Wijsman and Yu, 2004) . The founder family was analyzed as one pedigree, linked together by a common founder. Genotypes of 79 mutation carriers and 82 family members without GRN mutation were included in the analysis. Ages of individuals with the TARDBP p.G287S mutation and of their relatives DR404 II.1, II.2 and II.3 were excluded from analysis, since we could not exclude an effect on onset age (Fig. S2) . C9orf72 repeat length and APOE genotypes were analyzed as dichotomous variables. The normal lengths of the G 4 C 2 repeat were categorized as short (≤6 repeat 
GRN serum levels
Serum GRN levels were measured in duplicate in one experiment by a sandwich Enzyme LinkedImmunosorbent Assay (AdipoGen Life Sciences), according to manufacturers' instructions. The average intra-assay coefficient of variability was 4.85%. The individual coefficients of variability were deduced from the calculated concentrations by dividing the standard deviation of the duplicate measures by the duplicate average and multiplying by 100. Duplicate measurements were averaged for further analysis. Non-parametric Kruskal-Wallis or Mann-Whitney U test was used to compare levels between mutation carriers and control individuals and between mutation carriers with different genotypes at risk variations. Calculations were performed using SPSS version 22.
Correlation between onset age and GRN levels was assessed using a cox mixed effects model where kinship was included in the model to correct for relatedness. Calculations were performed using the R-packages coxme and kinship2 in R (R Core Team, 2014; Sinnwell et al., 2014) .
Haplotype sharing analysis
Polymorphic STR markers, located in and flanking the GRN founder haplotype at 17q21, were PCR amplified and the products were separated and analyzed on a 3730 DNA Analyzer (Applied
Biosystems) (Brouwers et al., 2007; van der Zee et al., 2006) . Genotypes were assigned using the inhouse developed TracI genotyping software.
Estimation of shared ancestry
The distance from index patients of the GRN founder family to the most recent common ancestor was estimated using Estiage software (Genin et al., 2004) . STR marker and haplotype data flanking the GRN mutation were included in the analysis for 13 index patients with phase-determined haplotypes. The allele frequencies were determined in unrelated control individuals (n=102). The recombination fractions were computed using the Kosambi mapping function. We assumed a stepwise mutation model which seems to hold better for STR loci and a mutation rate of 10 -4 or 10 -3 (Fan and Chu, 2007; Genin et al., 2004) . This corresponds to published mutation rates at STR loci, although these rates can vary greatly (Brinkmann et al., 1998) .
RESULTS
Belgian GRN founder family
Since the first description of the GRN founder family , the pedigree has been considerably extended. It currently consists of 29 branches of index patients carrying the GRN founder mutation (IVS1+5 G>C; p.0) and spans at least five generations (Fig. 1, Table 1 ). DNA is available of 175 family members, including 79 mutation carriers. The mutation so far, has only been identified in the Flanders-Belgian population. All carriers share a haplotype indicating that they are genetically related and belong to one founder pedigree (Table S1 ). The distance to the most recent common ancestor carrying the founder mutation, was estimated at 40 generations (95% confidence interval (CI) 27-58, mutation rate 10 -3
) by the Estiage program and increased to 46 generations (95% CI 32-67) when we considered a mutation rate of 10 -4 . Considering all patients in the pedigree, independent of the availability of DNA or clinical diagnosis, the onset age ranged from 45 to 80 years with an average of 63.1 ± 7.7 years (n=79) (Fig. 2) . The disease duration was 6.1 ± 3.8 years (n=66, range 1 to 20) and death occurred at 70.0 ± 7.2 years (n=72, range 49 to 85).
Phenotypic heterogeneity in GRN founder mutation carriers
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Clinical heterogeneity
For 40 of the 79 patients with onset age data, DNA material was available and a GRN founder mutation was identified. Three were obligate carriers, and had a clinical neurodegenerative disease diagnosis. Of these 43 patients, 32 were diagnosed with FTD (74%, spread over 21 branches of the pedigree), six with AD (14%, in six branches), two with PD (5%, in two branches), two with PD and dementia (PD+D) (5%, in two branches) and one with dementia unspecified (2%). Fifteen FTD patients (in 11 branches) were diagnosed with bvFTD, 14 patients (in 13 branches) with PPA and two with a mixed FTD phenotype (Table 2, Table S4 ).
Detailed clinical information was available for 38 patients. Thirteen FTD patients were diagnosed with bvFTD, of whom five had predominant symptoms of apathy (39%), five of disinhibition (39%), two of executive dysfunction (15%) and in one the predominant feature was unclear. Nine of 14 FTD patients with PPA had a non-fluent aphasia (64%), two a semantic dementia (14%) and three an unclear language subtype. Overall, behavioral and language symptoms were reported in 27 (71%) and 25 (66%) patients respectively. Apathy was the most frequent reported behavioral feature (67%) and word finding difficulties the most frequent reported language feature (52%). Although only five patients were diagnosed with AD, early memory problems were reported in 17 patients (45%) and early orientation problems in 11 patients (29%). Detailed findings of clinical neurological examinations were available for 32 patients. In nearly half of them (47%), extrapyramidal symptoms were present. Upper motor neuron symptoms were present in 11 patients (34%). An overview of the reported clinical symptoms and signs can be found in Table S2 and Table S5 .
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In 30 of 34 patient carriers, cerebral atrophy was reported. The atrophy was in most patients predominantly present in the frontal and/or temporal lobes (80%) and asymmetric in half of the patients (Fig. 3.1) . Parietal atrophy was reported in 24% (6/25) and hippocampal atrophy in 20%
(5/25). Abnormal findings on functional neuroimaging (FDG-PET (fluorodeoxyglucose PET) or perfusion SPECT) were reported for 22 of 23 patients of whom 13 had predominant frontal and/or temporal hypometabolism/-perfusion (Fig. 3.2) and 15 (68%) had additional or isolated parietal lobe involvement (Fig. 3.3) . In 20 patients (91%), the pattern of the functional abnormalities was reported to be asymmetric (Table S3 and Table S6 ). Dopamine transporter imaging was performed in three of the four PD patients and confirmed a presynaptic dopaminergic deficit.
GRN as modifier of onset age
We measured serum GRN levels of 22 founder mutation carriers from 17 branches (onset age 62.2 ± 9.3 year, range 45 to 76). The levels in GRN mutation carriers (median 27.3 ng/mL, range 12.8 to 39.8 ng/mL) were significantly lower (p=0.0001) in comparison to the levels measured in control individuals (median 74.2 ng/mL, range 56.2 to 90.3 ng/mL) with no overlap between both groups.
There was no evidence of correlation between onset age and GRN levels (Cox mixed effects p=0.41).
In the founder family the major C-allele of rs5848, situated in the GRN 3'UTR, is located on the mutant haplotype. The onset age of heterozygous rs5848 C/T carriers was on average 3.5 years earlier compared to C/C carriers (p=0.042, minor allele frequency (MAF)=0.23, Table 3 ). There were no differences in serum GRN levels between mutation carriers with a T-or C-allele on the normal haplotype (n=22, p=0.25).
Other modifiers of onset age
We did not observe a significant effect of the SORT1 and PSAP variants, TMEM106B rs1990622 and APOE ε4 on onset age, neither did we detect differences in serum GRN levels between patients carrying different genotypes at SORT1 and PSAP variations. Homozygous carriers of the MAPT H2 haplotype developed disease on average 7.8 years later than homozygous H1 carriers (p=0.032, MAF=0.36) ( Table 3) . We also identified a significant effect of the C9orf72 G 4 C 2 repeat size on onset M A N U S C R I P T In the founder pedigree, three quarters of the patients of whom we have a clinical diagnosis available received a clinical diagnosis of FTD, half bvFTD and half PPA. Apathy was the most frequent FTD behavioral feature and non-fluent progressive aphasia the most frequent PPA variant.
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Parkinsonism was reported in about half of the patients. On neuroimaging, asymmetric brain damage as well as parietal involvement was frequently reported. These findings are consistent with previous reports (e.g. (Beck et al., 2008; Rohrer et al., 2010; Whitwell et al., 2009) ). Other diagnoses were AD, unspecified dementia, PD and PD+D. Behavioral features were present in five and language symptoms in three of the eight patients with a non-FTD dementia diagnosis. In the five AD patients, the diagnosis was based on early episodic memory and/or orientation problems with parietal or more global involvement on neuroimaging. In one of them the CSF biomarker profile was in accordance with AD, while in three others the profile was not typical for AD. The three PD patients M A N U S C R I P T Fig. 3.4) (R.V., personal communication, 2016; Sieben et al., 2018) . In depth examination of nine patients revealed atherosclerotic changes of the small vessels in cortex and white matter as well as mild AD-related amyloid and/or tau pathology in all patients (Table 1 ) (Sieben et al., 2018) .
Patients carrying the GRN founder mutation received their clinical diagnosis in different hospitals
and different clinical settings between 1993 and 2014, implicating that the used diagnostic tools and standards were not in all patients equally advanced. This implies that some diagnoses might be misdiagnoses due to a lack of diagnostic tools at the time, such as FDG-PET or amyloid-PET of the brain or lumbar puncture to determine biomarker levels in CSF. However, the frequent combined pathology of FTLD-TDP type A with Alzheimer's and/or synucleinopathy features, suggests that at least a part of the heterogeneous clinical phenotype of GRN mutation carriers might be the result of additional pathologies. The question remains why additional neuropathological features occur frequently in GRN mutation carriers (Hosokawa et al., 2017; Kelley et al., 2009) . Given the function of GRN as a neurotrophic factor which enhances neuronal survival (Van Damme et al., 2008) , and the increased cellular aging that was postulated from the cytological changes seen in granulin knockout mice (Ahmed et al., 2010; Wils et al., 2012) , it is plausible that GRN haploinsufficiency lowers the threshold for other neurodegenerative pathologies or accelerates age-related neurodegeneration.
Related to this, it is interesting to note that variations in TMEM106B and GRN have recently been identified in a genome-wide association study for differential aging (Rhinn and Abeliovich, 2017) .
We observed in the founder pedigree a wide variability in onset age, ranging from 45 to 80 years, suggesting the influence of onset age modifiers. We investigated the effect of previously reported M A N U S C R I P T
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14 modifiers of onset age or disease risk. For the GRN rs5848 variation, homozygous carriers of the major C-allele developed symptoms on average 3.5 years later than heterozygous carriers of the risk T-allele. The variation is located in the 3'UTR within a binding site for miR-659. This miRNA binds more efficiently to the T-allele resulting in a translational inhibition of GRN (Rademakers et al., 2008 ). We did not identify a correlation between serum GRN levels and onset age, consistent with previous results (e.g. (Meeter et al., 2016; Sleegers et al., 2009) ) but in contrast with the finding of an earlier onset in patients with the lowest GRN levels (Ghidoni et al., 2012) . Analysis of the effect of the H1/H2 haplotypes of MAPT, which is located adjacent to GRN on chromosome 17, indicated that H2/H2 carriers develop disease on average 7.8 years later than H1/H1 carriers. Though, caution is needed in interpreting this result, because only three patients were homozygous H1/H1 carriers (onset ages 49 to 54 years) due to the location of H2 on the disease haplotype in most branches of the founder family. The effect on onset age is in agreement with the protective effect of H2 in progressive supranuclear palsy (Baker et al., 1999) . Of interest, also in Italian patients carrying the GRN p.Thr272SerfsX10 mutation, the MAPT haplotype is an onset age modifier; H2/H2 carriers developed disease later in comparison to patients with H1/H2 haplotypes (Benussi et al., 2009 ). In contrast, other studies in clinical FTD patients have reported an earlier disease onset in H2 carriers (Borroni et al., 2005; Laws et al., 2007) . Patients of the pedigree heterozygous for an intermediate C9orf72 G 4 C 2 repeat allele, developed disease on average 3.8 years earlier than patients with two short normal alleles. We could not detect a significantly lower onset age in carriers of two intermediate alleles, since there were only very few homozygous carriers of intermediate alleles, i.e.
one patient with onset age 70 years and two asymptomatic GRN mutation carriers aged 34 and 48
years. No onset age-modifying effects were observed for the genetic variations in the SORT1 and PSAP loci. We could not replicate a significant difference in serum GRN levels between patients with different genotypes (Carrasquillo et al., 2010; Nicholson et al., 2016 ), but we cannot exclude that the low number of samples limited the detection of subtle differences in GRN levels. Consistent with our earlier results, no significant onset age modifying effect of TMEM106B rs1990622 or APOE ε4 was M A N U S C R I P T
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15 observed van der Zee et al., 2011) . Although we did not see an onset age modifying effect of the rs1990622 variation, we did notice that none of the affected mutation carriers was homozygous carrier of the protective C-allele, supporting a protective effect of TMEM106B rs1990622. Variations in TMEM106B have been identified as a risk factor for FTLD-TDP, with the greatest effect in GRN mutation carriers (Van Deerlin et al., 2010) . Furthermore, an effect on onset age has been observed in GRN mutation carriers (Cruchaga et al., 2011) .
For the loci we investigated, positive as well as negative associations with disease or onset age have been reported indicating that studies in larger cohorts will be needed to obtain solid results (e.g. (Rademakers et al., 2008; Rollinson et al., 2011; Rubino et al., 2013; Van Deerlin et al., 2010; van der Zee et al., 2011) ). It is possible that small effects were detected in some families or cohorts, while in other groups of patients the effect did not reach statistical significance. Also in our study, effect sizes were small and would not reach statistical significance in a genome-wide study of modifier variations. GRN, MAPT and C9orf72 repeat length explained 2.7%, 4.4% and 5.6% of the variability in onset age in the pedigree, indicating the involvement of other modifying factors. One possibility is that pathogenic mutations in other causal genes associated with neurodegenerative brain diseases could exert a modifying effect. In one branch of the pedigree, we identified the p.G287S mutation in TARDBP (Fig. S2) , a well-established causal gene for amyotrophic lateral sclerosis (Kabashi et al., 2008; Sreedharan et al., 2008) . Rare TARDBP mutation carriers have also been identified who present clinically with FTD (Borroni et al., 2010) . Since only one non-affected individual carrying both the GRN founder mutation and the TARDBP mutation was identified in the founder family, we cannot make a firm statement about the potential of a modifying effect on disease presentation.
The phenotypic heterogeneity in patients carrying the same GRN mutation, emphasizes that 
